Synergy Pharmaceuticals — Investor Presentation (October 2009)
21 slides from Synergy Pharmaceuticals's investor presentation, Oct 9, 2009
Slide 1: Synergy Pharmaceuticals: GI Drug Company
1 Gary S. Jacob, Ph.D. President & CEO October 12, 2009 GI Drug Company focused on Drugs to treat GI Disorders and Diseases (SGYP.OB)
Slide 2: Forward-looking statements
2 SYNERGY PHARMACEUTICALS, INC. Certain statements made in this presentation are forward-looking. Such statements are indicated by words such as “expect,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Synergy believes that the expectations reflected i
Slide 3: Overview
3 OVERVIEW Symbol & Exchange: SGYP (OTCBB) Proprietary Technology – GC-C Receptor Agonists Focused Business Strategy Experienced Management Team Presently have 75 million common shares outstanding, no warrants, preferred stock, convertibles or debt instruments More than $11 million raised last 12 mo
Slide 4: History of GC-C Receptor agonists to Treat GI Disorders & Diseases
4 History of GC-C Receptor agonists to Treat GI Disorders & Diseases Researchers from Monsanto/Searle eventually joined two biotechnology companies, Microbia and Synergy Ironwood (Microbia) aggressively developing its compound – linaclotide for GI disorders Synergy files first patent applications –
Slide 5: Guanylate Cyclase C Receptors - Physiological mechanism
5 Guanylate Cyclase C Receptors - Physiological mechanism Guanylate Cyclase C (GC-C) receptors are present on luminal side of gut Key regulator of salt and liquid content of gut The CFTR when activated secretes Cl- and HCO3 - into intestinal lumen, along with water
Slide 6: Synergy Portfolio
6 SP-304 for GI disorders (chronic constipation & IBS-C) SP-333 for ulcerative colitis & IBD GC-C agonists for other disease indications Synergy Portfolio Synergy’s GC-C Receptor Agonist Program is a Technology Platform
Slide 7: SP-304 to Treat GI Disorders & Diseases
7 SP-304 to Treat GI Disorders & Diseases Oral drug for GI disorders Analog of human peptide hormone uroguanylin Virtually no systemic absorption – low risk of toxicity Exceptionally low development risk...following first-in-class drug presently in Phase 3 for GI disorders Clinical proof-of-principl
Slide 8: Lead drug: SP-304 – A GC-C Receptor Agonist
8 Lead drug: SP-304 – A GC-C Receptor Agonist NDDCELCVNVACTGCL Uroguanylin Natural Hormone NDECELCVNVACTGCL SP-304 Uroguanylin Analog Single letters denote different amino acids. Colored lines denote disulphide bonds 16-mer analog of uroguanylin Single key amino acid change Locked into stable active
Slide 9: Activation of chloride channels increases fluid secretion into GI lumen
9 Activation of chloride channels increases fluid secretion into GI lumen Amitiza® SP-304 Linaclotide
Slide 10: SP-304 Clinical Development – Phase I Trial in Volunteers
10 SP-304 Clinical Development – Phase I Trial in Volunteers “Single-site, Randomized, Double-blind, Placebo-Controlled, Single-, Ascending-, Oral-Dose Safety, Tolerability, and Pharmacokinetic Study of SP-304 in Healthy Adult Human Male and Female Volunteers" (Protocol No. SP-SP304101-08) Cohorts a
Slide 11: SP-304: Rationale for Potential as 'Best-in-Class'
11 NDECELCVNVACTGCL SP-304 Uroguanylin Analogue Red & blue colored lines denote disulphide bonds Modulates binding constant with mucosal acidity Defines agonist activity SP-304: Rationale for Potential as ‘Best-in-Class’ • Mucosal acidity provide physiological ‘ON’ and ‘OFF’ switch for modulating bi
Slide 12: SP-304 Clinical Development Strategy
12 SP-304 Clinical Development Strategy Three SP-304 clinical trials planned for CIC and IBS-C Phase 2a seven-day repeated-dose, placebo-controlled dose escalation Phase IIa trial in CIC patients (N = 60) Phase 2b 28-day dose-ranging, placebo-controlled Phase 2b trial in CIC patients (N= 320) Key pr
Slide 13: SP-304 Clinical Development Timeline
13 SP-304 Clinical Development Timeline • SP-304 manufacture scale-up underway • SP-304 formulation presently underway Initiate Phase 2a 7-day CC trial Initiate Phase 2b 28-day, fixed dose 28-day CC clinical trial Expect clinical data to be available to set doses for 28-day trial Jan.2010 Feb.2010 S
Slide 14: GC-C Receptor Agonist Studies in Animal Models of Ulcerative Colitis
14 GC-C Receptor Agonist Studies in Animal Models of Ulcerative Colitis Efficacy of GC-C agonists (eg. SP-304) has been validated in three different acute animal models of ulcerative colitis - TNBS-induced colitis in Balb/c mouse - TNBS-induced colitis in BDF1 mouse - DSS-induced colitis in BDF1 mou
Slide 15: TNBS Injected Balb/c mice treated with SP-304 show histological improvement
15 TNBS Injected Balb/c mice Treated with SP-304 show histological improvement and suppressed intestinal secretion of pro-inflammatory cytokines 0 40 80 120 IL-12 p40 IL-23 TNF Cytokines, pg/ml Control SP304, 50 µg/day 160 0 5 10 15 20 25 Histopathology Score SP-304 (µg/day) 0 10 20 50 n-9 n-8 n-4 n
Slide 16: SP-333 Development for Ulcerative Colitis
16 SP-333 Development for Ulcerative Colitis Phase I single-dose, dose-escalation trial in healthy volunteers Safety, tolerability and PK of orally administered SP-333 To be followed by evaluation in ulcerative colitis patients
Slide 17: Corporate Structure & Management
17 Corporate Structure & Management Gary S. Jacob, Ph.D.; President & CEO 20 years experience in drug discovery & development G.D. Searle, Monsanto Co., Oxford University Kunwar Shailubhai, Ph.D., MBA; Chief Scientific Officer > 15 years experience at G.D. Searle/Monsanto Co. and NIH Major discovere
Slide 18: Board of Directors
18 Board of Directors Gabriele Cerrone, Chairman Thomas H. Adams, Ph.D John Brancaccio Gary S. Jacob, Ph.D.; President & CEO Alan F. Joslyn, Ph.D. Chris McGuigan, Ph.D. Melvin Spigelman, MD Allen Mangel, M.D., Ph.D. – Clinical Development Authority on clinical development of GI drugs Hoyle Group – R
Slide 19: Scientific advisors
19 Douglas Drossman, M.D. Dr. Drossman is Professor of Medicine and Psychiatry (UNC School of Medicine, Division of Gastroenterology & Hepatology) and Co-Director of the UNC Center for Functional GI & Motility Disorders Michael Camilleri, M.D., Ph. D. Dr. Camilleri is Professor of Physiology and Med
Slide 20: Summary
20 Summary Synergy’s platform of GC-C receptor agonists for therapeutics Lead compound SP-304 - Plus 2nd generation compound, SP-333 Several other uses possible beyond GI disorders and IBD GC-C receptor agonists are a new class of potential drugs Peptide hormone analogs to treat gastro-intestinal di
Slide 21: Future Synergy Value Creation Milestones
21 Future Synergy Value Creation Milestones *1Q2010 – Initiate SP-304 Phase 2a 7-day CC trial *4Q2010 – Phase 2a clinical data *2010 – File IND on SP-333 1Q2011 – Initiate SP-304 Phase 2b 28-day CC trial 3Q2011 – Initiate SP-304 Phase 2b 90-day IBS-C trial * Key 2010 Future Value-Creation Events
Synergy Pharmaceuticals — Investor Presentation (October 2009) on 6ix